Adverum Biotechnologies, Inc.
(NASDAQ : ADVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.97%177.801.3%$462.64m
CELGCelgene Corporation
0.98%97.461.3%$422.24m
GILDGilead Sciences, Inc.
1.30%67.220.9%$393.54m
BIIBBiogen Inc.
1.70%231.551.3%$353.45m
ILMNIllumina, Inc.
1.30%348.463.5%$271.42m
REGNRegeneron Pharmaceuticals, Inc.
1.33%309.312.6%$232.04m
AAgilent Technologies, Inc.
0.56%70.361.6%$213.26m
VRTXVertex Pharmaceuticals Incorporated
1.37%172.551.9%$196.84m
EXASExact Sciences Corporation
1.78%111.7325.3%$186.13m
ARRYArray BioPharma Inc.
56.86%46.428.2%$185.97m
ALXNAlexion Pharmaceuticals, Inc.
3.08%121.572.0%$177.48m
BMRNBioMarin Pharmaceutical Inc.
3.87%83.974.3%$135.87m
MRTXMirati Therapeutics Inc.
5.18%99.142.5%$112.56m
IONSIonis Pharmaceuticals, Inc.
2.98%63.948.2%$95.87m
INCYIncyte Corporation
5.61%82.072.5%$92.20m

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.